Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1569 8041 "

Sökning: L773:1569 8041

Sortera/gruppera träfflistan
  • Aapro, M, et al. (författare)
  • Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
  • 2008
  • Ingår i: Annals of Oncology. - : Oxford University Press. - 1569-8041 .- 0923-7534. ; 19:3, s. 420-432
  • Tidskriftsartikel (refereegranskat)abstract
    • Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, and have substantially decreased the prevalence of such events since their introduction. Today, a broad range of BP with differences in potency, efficacy, dosing, and administration as well as approved indications is available. In addition, results of clinical trials investigating the efficacy of BP in cancer treatment-induced bone loss (CTIBL) have been recently published. The purpose of this paper is to review the current evidence on the use of BP in solid tumours and provide clinical recommendations. An interdisciplinary expert panel of clinical oncologists and of specialists in metabolic bone diseases assessed the widespread evidence and information on the efficacy of BP in the metastatic and nonmetastatic setting, as well as ongoing research on the adjuvant use of BP. Based on available evidence, the panel recommends amino-bisphosphonates for patients with metastatic bone disease from breast cancer and zoledronic acid for patients with other solid tumours as primary disease. Dosing of BP should follow approved indications with adjustments if necessary. While i.v. administration is most often preferable, oral administration (clodronate, IBA) may be considered for breast cancer patients who cannot or do not need to attend regular hospital care. Early-stage cancer patients at risk of developing CTIBL should be considered for preventative BP treatment. The strongest evidence in this setting is now available for ZOL. Overall, BP are well-tolerated, and most common adverse events are influenza-like syndrome, arthralgia, and when used orally, gastrointestinal symptoms. The dose of BP may need to be adapted to renal function and initial creatinine clearance calculation is mandatory according to the panel for use of any BP. Subsequent monitoring is recommended for ZOL and PAM, as described by the regulatory authority guidelines. Patients scheduled to receive BP (mainly every 3-4 weeks i.v.) should have a dental examination and be advised on appropriate measures for reducing the risk of jaw osteonecrosis. BP are well established as supportive therapy to reduce the frequency and severity of skeletal complications in patients with bone metastases from different cancers.
  • Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
  • 2009
  • Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. - 1569-8041. ; 21:2, s. 245-254
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. PATIENTS AND METHODS: Patients participated in two International Breast Cancer Study Group randomized trials testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or postmenopausal (trial IX) node-negative breast cancer. PVI was assessed by institutional pathologists and/or central review on hematoxylin-eosin-stained slides in 99% of patients (analysis cohort 2754 patients, median follow-up >9 years). RESULTS: PVI, present in 23% of the tumors, was associated with higher grade tumors and larger tumor size (trial IX only). Presence of PVI increased locoregional and distant recurrence and was significantly associated with poorer disease-free survival. The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of goserelin was limited to patients whose tumors showed PVI. In trial IX, all patients received tamoxifen: the adverse prognostic impact of PVI was limited to patients with receptor-negative tumors regardless of chemotherapy. CONCLUSION: Adequate endocrine adjuvant therapy appears to abrogate the adverse impact of PVI in node-negative disease, while PVI may identify patients who will benefit particularly from adjuvant therapy.
  • Alkner, Sara, et al. (författare)
  • AIB1 is a predictive factor for tamoxifen response in premenopausal women
  • 2010
  • Ingår i: ANNALS OF ONCOLOGY. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 21:2, s. 238-244
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Clinical trials implicate the estrogen receptor ( ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry. Results: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm, high AIB1 was a negative prognostic factor for recurrence- free survival (RFS) (P = 0.02). However, ER-positive patients with high AIB1 responded significantly to tamoxifen treatment (P = 0.002), increasing RFS to the same level as for systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS from the beginning, this was not further improved by tamoxifen (P = 0.8). Conclusions: In the control group, high AIB1 was a negative prognostic factor. However, ER-positive patients with high AIB1 responded significantly to tamoxifen. This implicates high AIB1 to be an independent predictive factor of improved response to tamoxifen and not, as has previously been discussed, a factor predicting tamoxifen resistance.
  • Alkner, Sara, et al. (författare)
  • The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
  • 2013
  • Ingår i: Annals of Oncology. - : Oxford University Press. - 1569-8041 .- 0923-7534. ; 24:5, s. 1244-1252
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P < 0.001) in systemically untreated women, while no prognostic effect was seen in the tamoxifen-treated cohort, indicating AIB1 to be a predictor of tamoxifen response. In systemically untreated patients, PAX2 was not a prognostic factor, nor did it modify the effect of AIB1. However, in ER-positive patients receiving tamoxifen, PAX2 appeared to be a positive prognostic factor in premenopausal patients, while a negative factor in postmenopausal. The interaction between the menopausal status and PAX2 was significant (P = 0.01).ConclusionsIn an independent cohort of low-risk premenopausal patients, we validate AIB1 as a negative prognostic factor, indicating AIB1 to be an interesting target for new anti-cancer therapies. The effect of PAX2 warrants further studies.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (400)
konferensbidrag (19)
forskningsöversikt (13)
Typ av innehåll
refereegranskat (350)
övrigt vetenskapligt (81)
populärvet., debatt m.m. (1)
Glimelius, Bengt (39)
Bergh, J (29)
Öberg, Kjell (20)
Hemminki, Kari (13)
Cardoso, F (13)
Pfeiffer, P (13)
visa fler...
Aapro, M (12)
Boffetta, P (12)
La Vecchia, C (11)
Harbeck, N (11)
Adami, HO (11)
Sundquist, Jan (11)
Berglund, Åke (11)
Gnant, M. (10)
Thürlimann, B. (10)
Viale, G (10)
Weiderpass, E (9)
Kaaks, R. (9)
Tumino, R. (9)
Riboli, E. (9)
Trichopoulou, A (9)
Cohn-Cedermark, G (9)
Sorbye, H. (9)
Jordan, K (8)
Bueno-de-Mesquita, H ... (8)
Sundquist, Kristina (8)
Horwich, A (8)
Cunningham, D (8)
Vineis, P (8)
Palli, D (8)
Hemminki, K (8)
Bellocco, R (8)
Barricarte, A (8)
Helleday, T (8)
Andre, F (8)
Jenab, M (8)
Pavel, M. (8)
Overvad, K (7)
Quiros, J. R. (7)
Goldhirsch, A (7)
Hatschek, T (7)
Jerkeman, Mats (7)
Eriksson, Mikael (7)
Fizazi, K (7)
Oldenburg, J (7)
Panico, S (7)
Öberg, Kjell, 1946- (7)
Vergote, I. (7)
Van Cutsem, E (7)
Francis, P (7)
visa färre...
Karolinska Institutet (222)
Uppsala universitet (117)
Lunds universitet (97)
Umeå universitet (42)
Linköpings universitet (28)
Göteborgs universitet (24)
visa fler...
Örebro universitet (13)
Jönköping University (4)
Kungliga Tekniska Högskolan (3)
Karlstads universitet (3)
Stockholms universitet (2)
Mälardalens universitet (1)
Högskolan i Skövde (1)
Chalmers tekniska högskola (1)
Högskolan i Gävle (1)
Sveriges Lantbruksuniversitet (1)
Marie Cederschiöld högskola (1)
visa färre...
Engelska (432)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (231)
Naturvetenskap (2)
Samhällsvetenskap (2)
Teknik (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy